NDA acceptance with Priority Review and no AdCom is a strong positive signal. The PDUFA date of Nov 30, 2026 provides a clear catalyst. ASCO presentation on May 30 may drive near-term volatility. Monitor for any CRL or review issues ahead of PDUFA; the stock has historically underperformed post-reports (avg T+20 -6.73%), but this is a fundamentally different event — a regulatory acceptance with breakthrough designation and no identified issues.
Price Chart
Executive Summary
Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Priority Review and a PDUFA date of November 30, 2026. The Phase 3 PEAK trial showed a median PFS of 16.5 months vs 9.2 months (HR=0.50, p<0.0001) and a 46% ORR vs 26% for sunitinib alone. This is a major regulatory milestone for a first-in-class combination that could transform second-line GIST treatment, with no advisory committee planned and no identified review issues.
Key Facts
- FDA accepted NDA for bezuclastinib + sunitinib in GIST with Priority Review; PDUFA date November 30, 2026
- Phase 3 PEAK trial: median PFS 16.5 months (combination) vs 9.2 months (sunitinib alone); HR=0.50 (95% CI: 0.39-0.65, p<0.0001)
- ORR 46% for combination vs 26% for sunitinib monotherapy in imatinib-resistant patients
- No advisory committee planned; FDA communicated no potential review issues identified
- Full PEAK results to be presented at ASCO oral session on May 30, 2026
- Company preparing for launches in both GIST and systemic mastocytosis later this year
- Expanded Access Programs established for U.S. patients with GIST or SM
Financial Impact
First approval for a novel KIT inhibitor combination in GIST; potential peak sales in the hundreds of millions to billions given GIST prevalence and clear superiority over standard of care
Risk Factors
- FDA could issue a Complete Response Letter at PDUFA despite current positive signals
- Hepatic safety signals (ALT/AST elevations) could become a review focus
- Commercial launch execution risk in both GIST and SM
- Overall survival data remains immature; negative OS readout could limit label expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302753 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access